Compare FCPT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2015 | 1996 |
| Metric | FCPT | VCEL |
|---|---|---|
| Price | $24.18 | $37.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $28.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 553.9K | 428.3K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | 1.87 | ★ 60.00 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $294,132,000.00 | $276,259,000.00 |
| Revenue This Year | $6.66 | $19.40 |
| Revenue Next Year | $8.28 | $18.24 |
| P/E Ratio | $44.58 | ★ N/A |
| Revenue Growth | 9.72 | ★ 16.45 |
| 52 Week Low | $22.78 | $28.95 |
| 52 Week High | $26.86 | $49.32 |
| Indicator | FCPT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 28.21 |
| Support Level | $24.06 | $35.45 |
| Resistance Level | $25.66 | $39.48 |
| Average True Range (ATR) | 0.31 | 1.10 |
| MACD | -0.07 | -0.32 |
| Stochastic Oscillator | 4.25 | 1.51 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.